Moreover, the fact that the PPARγ antagonist, GW9662, was shown to completely reverse the liver lipid accumulation in mice deficient for SMURF1, suggests that activation of SMURF1-dependent non-proteolytic ubiquitylation could be exploited as a new strategy for NAFLD treatment. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.